Targeted Oncology1d
FDA Grants PYX-201 Fast Track Status in HNSCC
PYX-201 has gained FDA fast track designation in recurrent or metastatic head and neck squamous cell carcinoma.
FDA grants fast track status to Pyxis’ PYX-201
The US Food and Drug Administration (FDA) has granted fast track designation to Pyxis Oncology’s antibody-drug conjugate (ADC ...
manilatimes2d
Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer
Designation applies to the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma ...
manilatimes2d
Rekor's Vehicle Insite Application Deployed to Study Electric Vehicle Movement Across 90 Sites in the Phoenix Metropolitan Area
Vehicle Insite provides detailed vehicle analytics, including class, count, speed, and state of origin, offering planners a holistic view of roadway usage. Its EV analytics identify EV volumes and ...
Pyxis Oncology granted Fast Track designation for PYX-201 monotherapy
Pyxis Oncology (PYXS) announced that the U.S. Food and Drug Administration has granted Fast Track Designation to PYX-201 for the treatment of ...
Pyxis Oncology rises on FDA fast track tag for lead asset
Pyxis Oncology (PYXS) stock rises as the FDA issues fast track designation for its lead asset PYX-201 in head and neck cancer ...